In-Depth Examination Of 6 Analyst Recommendations For DexCom
Portfolio Pulse from Benzinga Insights
DexCom (NASDAQ:DXCM) has been analyzed by six analysts, revealing a range of sentiments from bullish to indifferent. The average 12-month price target has increased to $154.0, with a high estimate of $165.00 and a low estimate of $130.00. Recent ratings include a mix of 'Strong Buy', 'Buy', 'Outperform', and 'Neutral'. DexCom's financial health is strong, with notable revenue growth, high net margins, and effective asset utilization, though it carries a substantial amount of debt.
May 30, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DexCom has received mixed analyst ratings, with an average 12-month price target of $154.0. The company's financial health is strong, with significant revenue growth and high net margins, but it carries a substantial amount of debt.
The mixed analyst ratings, with a majority being positive, and the increase in the average price target suggest a positive short-term impact on DexCom's stock price. The company's strong financial health further supports this outlook, although the high debt level is a potential risk factor.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100